v," Forty patients with recurrent gliomas were treated with monthly intra-arterial infusions of cisplatin. Of the 35 evaluable patients, 12 (34%) responded with computerized tomography (CT) evidence of a decrease in tumor size; in 14 (40%) the tumor stabilized on CT scans, and in nine (26%) the disease progressed. The median survival period was 35.0 weeks for the responders and 27.5 weeks for all 35 patients. The primary toxicities were renal (reversible alterations in creatinine clearance), otological (severe hearing loss in one patient), and likely neurotoxicity in one patient who had received bilateral infusions following contralateral tumor progression. The authors are now using this form of regional chemotherapy sequentially before and following radiotherapy in newly diagnosed cases.
A
LTHOUGH the very first investigations of chemotherapy in the management of malignant gliomas in the 1950s utilized intra-arterial routes of administration, 4"~2"27 effective agents were first identified in the 1970's in clinical trials of systemic 1,3-bis(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (BCNU) chemotherapy. 3"26 Since then, a number of agents have been shown to provide a definite although modest antiglioma effect following intravenous administration. It was not until the 1980's that a significant interest in intra-arterial chemotherapy for treatment of giiomas resumed. One drug of particular interest that was administered by the intra-arterial route was cisplatin, an inorganic chelator heavy-metal complex, which is a cell-cycle nonspecific drug interfering primarily with deoxyribonucleic acid (DNA), ribonudeic acid (RNA), and protein synthesis. Cisplatin is water-soluble and has a plasma half-life of approximately 1 hour with a secondary phase of 2 to 3 days. The drug appears to be protein-bound, with 25% to 50% excreted via the kidney. Intra-arterial administration of cisplatin is believed to deliver a higher concentration of drug to the area of tumor, in which there is presumed to be an altered blood-brain barrier.
Our experience of intra-arterial cisplatin chemotherapy in patients with recurrent progressive gliomas is reported here, and the clinical literature regarding intraarterial chemotherapy for gliomas, including toxicities and efficacies, is discussed.
Clinical Material and Methods

Patient Population
Forty patients with recurrent progressive gliomas were treated with intra-arterial infusions of cisplatin. Five of these patients were not evaluable because computerized tomography (CT) was not performed after the first treatment due to failure of the patient to return for follow-up examination. Therefore, this report reflects our experience with 35 patients, 20 men and 15 women, whose ages ranged from 25 to 69 years (average 40.3 years). Histopathological examination of the tissue most recently resected revealed that 20 patients (57%) had glioblastoma multiforme, 14 patients (40%) had anaplastic astrocytomas, and one patient (3%) had astrocytoma. All patients had previously been treated with external beam radiation therapy as part of their initial treatment and many had subsequently received systemic chemotherapy (Table 1) .
Preinfusion Evaluation
Prior to treatment, all patients underwent baseline neurological examination, Karnofsky performance status evaluation, and CT scanning (enhanced and unen-hanced). The CT scans revealed that each tumor was anatomically located so as to likely receive its major blood supply from the ipsilateral internal carotid artery. Neurological examinations and Karnofsky functional rating were performed monthly prior to each infusion, and CT scanning was performed at least every 8 weeks (for the most part monthly). An attempt was made to standardize the scanning technique by using a bolus intravenous injection of contrast medium (150 ml Angiovist) and beginning the scan sequence (axial 10-mm slices) within 1 minute thereafter. All serial evaluations were compared with the baseline prechemotherapy data as well as with any subsequent previous examinations. Volumes of enhancing mass were determined from the CT scans, excluding surrounding edema but including any enclosed area of low density. Tumor volumes were computed by one of the authors by adding the tumor volumes calculated from the two greatest perpendicular distances of enhancing tumor measured from each lOmm slice.
Prior to each cisplatin infusion, the patients underwent the following blood studies: complete blood count including differential, serum electrolytes, liver enzymes, creatinine, and blood urea nitrogen levels. Each patient 7  420  32  281+  4  39, M  70  GBM  S, R  2  120  --5  30, M  90  GBM  S, R, C  2  120  8  25  6  32, M  100  AA  S, R, C  6  360  20  36  7  33, M  90  AA  S, R  2  120  6  6  8  42, F  50  GBM  S, R  1  60  3  8  9  29, M  90  AA  S, R, C  2  120  11  19  10  57, F  50  GBM  S, R, C  1  60  --11  27, F  90  astro  S, R  6  360  21:~  35  12  37, F  60  AA  S, R, C  7  420  220+  13  54, F  50  AA  S, R, C  1  60  --14  67, M  70  GBM  S, R, C  1  60  --15  53, M  70  GBM  S, R, C  4  240  17  34  16  57, M  90  GBM  S, R, C, I  4  240  27  40  17  54, F  90  GBM  S, R, I  3  180  13  16  18  69, F  70  GBM  S, R, C  3  180  46  46  19  35, F  70  AA  S, R  2  120  7w  15  20  32, M  90  GBM  S, R, C, I  5  300  20  30 * GBM = glioblastoma multiforme; AA = anaplastic astrocytoma; astro = astrocytoma; oligo = oligodendroglioma. S = surgery; C = chemotherapy; R = radiation therapy; I = immunotherapy. t Failure = time at which computerized tomography (CT) showed a > 25% increase in enhancing tumor volume. also underwent 24-hour urine creatinine clearance tests and audiography. Treatment was delayed for the following reasons: hematocrit less than 30%; white blood cell count less than 3000/ml; platelet count less than 100,000/ml; blood urea nitrogen levels greater than 20 mg dl; serum creatinine content greater than 1.2 mg/ dl; bilirubin levels greater than 2.0 mg/dl; or creatinine clearance less than 50 ml/min.
Drug Administration
All patients were hydrated with 5% dextrose in 50% normal saline infused intravenously at 250 cc/hr for at least 2 hours prior to intracarotid cisplatin infusion. Each patient was premedicated with: atropine, 0.4 mg intramuscularly; dexamethasone, 20 mg intravenously; metoclopramide, 2 mg/kg intravenously; and diphenhydramine, 50 mg as an intravenous infusion over 15 to 30 minutes. All intracarotid infusions were performed in the neuroangiography suite, with monitoring of blood pressure and electrocardiography. Under fluoroscopic guidance, a catheter was placed via the femoral artery into the internal carotid artery ipsilateral to the tumor, at the level of the C-2 vertebra. Patients then received further medication with nalbuphine hydrochloride, 20 to 30 mg intravenously, for sedation during the infusion which generally lasted from 30 to 45 minutes.
Cisplatin was administered in a dose of 60 mg/sq m body surface area, dissolved in sterile water in a concentration of l mg/ml. The drug was given by continuous infusion using en injector gun, set at a rate of 2 to 4 ml/min. Following completion of the cisplatin infusion, the patients were hydrated intravenously at a rate of 75 ml/hr until the following morning. Each patient was also medicated with metoclopramide, 1 mg/ kg, intravenously every 2 hours for two doses and then every 3 hours for two doses, for a total of four doses. Most patients slept throughout the afternoon and evening following their infusion. The majority of the patients had some mild nausea and vomiting the evening following their infusion but this typically had resolved by the next morning. Patients were discharged on the morning following their infusion.
Treatment Evaluation
The primary measure of the effectiveness of intracarotid cisplatin in this study was the CT scan response. In addition, each patient was followed to determine time to treatment failure and the period of survival following treatment. The enhancing tumor volume was determined from the serial CT brain scans for comparison with the volume on the baseline CT tumor image obtained just prior to the start of treatment. The responses were expressed as a ratio of tumor volume on the follow-up scan to tumor volume on the baseline scan. "Responders" were those patients who showed a greater than 25 % reduction in enhancing tumor volume in the absence of any increase in steroid dosage. "Stable" patients were those who had a less than 25% change in enhancing tumor volume in the absence of any increase in steroid dosage. "Progression" was defined as a greater than 25 % increase in enhancing tumor volume in the absence of decreased steroid dosage or a lesser increase in tumor volume associated with an increase in steroid dosage necessitated by neurological worsening. Time to treatment failure was that time between initiation of cisplatin treatment and CT scan documentation of progression, unless otherwise noted. The period of survival was that time between initiation of cisplatin treatment and either death of the patient or termination of this review (December 31, 1987) .
Serial neurological examinations, although not used to assess response to therapy, were compared to the baseline preinfusion examinations for the purpose of steroid adjustments. Results were expressed as improved, no change, or worse. The patients were further analyzed as regards age, Karnofsky rating, initial tumor volume, number of infusions, total cisplatin dose, and histopathology as well as time to treatment failure and survival.
Results
This series included 40 patients with recurrent progressive gliomas who were treated with carotid artery cisplatin infusions (Table 1) . Of this group, 35 patients were evaluable with follow-up CT scans and were included as the study group for detailed evaluation. Seven of these patients are still alive between 21 and 28 weeks after beginning treatment. None of these seven patients is currently being treated, and two of them have not met the CT scan criteria for failure; these two patients (Cases 12 and 39) were treated for 1 year and are currently stable. For all cases, the mean/median time to treatment failure (33 cases) was 16.3/12.0 weeks and the mean/median survival times (35 cases) were 40.6/ 27.5 weeks (Fig. 1 ). 
Treatment Responder Group
A total of 12 patients (34% of the study group) met the CT scan criteria as responders to cisplatin (Table  2) . This group received a mean of 4.3 infusions and a mean total dose of 260 mg/sq m of cisplatin (Table 3) . Seven of these patients had glioblastoma multiforme, four had anaplastic astrocytoma, and one had astrocytoma. The censored median survival time of this group was 35.0 weeks, with two of these patients still alive (Fig. 2) . The mean/median time to failure for 11 of these 12 patients was 22.6/20.0 weeks (Fig. 3 and Table  4) ; two of these patients (Cases 19 and 26) did not fail on the basis of ipsilateral tumor progression but instead showed contralateral extension of tumor at 7 and 23 weeks, respectively. For this responder group, the mean Karnofsky rating was 76, the mean initial tumor volume was 61 cu cm, and the mean age was 40 years (Table 3) . Reductions in tumor size in this group ranged from 80% to 25% of the baseline volume. Six of the patients responding by CT scan criteria demonstrated neurological improvement. Four of these six patients plus two others with stable neurological examinations had steroid reduction during treatment.
Disease Stabilization Group
Fourteen (40%) of the 35 patients met the study definition for patients with a stable response to the chemotherapy (Table 5) . Four of these patients are still alive. This group received a mean of 3.6 courses of cisplatin and a mean total dose of 218 mg/sq m of body surface area (Table 3) . Seven patients had glioblastoma multiforme and seven had anaplastic astrocytoma. The censored median survival time for the stable group was 24.0 weeks (Fig. 2) , and the mean/median time to failure for 13 patients in this group was 19.1/t 4.0 weeks (Fig. 3 and Table 4 ). The mean Karnofsky rating for this group was 83, the mean baseline tumor volume was 56 cu cm, and the mean age was 40 years (Table  3) . Three patients had modest improvements of their neurological findings even though tumor volume was 
Disease Progression Group
Nine (26%) of the patients in this study were considered to have disease progression since the beginning of chemotherapy (Table 6 ). This group received a mean of 1.3 courses of cisplatin and a mean total dose of 93 mg/sq m of body surface area (Table 3) . Only two patients received more than one intracarotid injection of cisplatin, due to the fact that the patients' neurological status was still satisfactory despite CT scan changes. Of these nine patients, six had glioblastoma multiforme and the other three had anaplastic astrocytoma. Treatment failure in this group was documented at a mean/ median of 4.8/4.0 weeks (Fig. 3 and Table 4 ). The censored median survival time was short, only 14.0 weeks (Fig. 2) . Interestingly, the mean initial Karnofsky rating of this group was 77 and the mean age was 42 * The CT data show follow-up enhancing tumor volume as a percentage of baseline tumor volume. Neurological examination (NE) is described as improved (+), stable (0), or worse (-), as compared to the prior examination. ND = not done.
t Due to neurological change, steroids had to be increased between baseline, treatment, and the l-month follow-up evaluation. years, almost identical with the responder and stable groups (Table 3) . Although the baseline mean tumor volume (_ standard deviation) for this group was 67 ___ 19 cu cm compared to 58 -46 cu cm for the stable and responder groups, this 16% mean greater initial tumor volume for the progression group was not significant (Student's t-test).
Toxicity
Twenty-two (63%) of the 35 patients exhibited some degree of toxicity. Nephrotoxicity, defined as a decrease in urinary creatinine clearance, was documented in 13 cases (37%), but required cessation of therapy in only two cases (Cases 18 and 21) . In two additional patients, nephrotoxicity required delays in therapy. The reductions of creatinine clearance ranged from 20% to 67% below baseline values. In the majority of these cases, the reduction in creatinine clearance was apparent during the second infusion and was completely reversible with time.
Ototoxicity, identified from serial audiograms obtained prior to each infusion, occurred in eight cases (22%) and consisted of a mild to modest decrease in high-frequency hearing (Fig. 4) . The fact that hearing loss occurred bilaterally suggests that this toxicity was a systemic effect of the drug as opposed to a local effect related to the side of infusion. Only one patient experienced unilateral hearing loss on the side of the infusion. No delay or discontinuation of therapy was necessitated as a result of ototoxicity.
Bone marrow suppression was observed in 15 patients (43%), requiring delays in subsequent therapy in only two. The most frequently observed abnormality was a reduction in hematocrit. This was generally mild in all patients, with hematocrits dropping to less than 30% in only two patients. White blood cell counts were 
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Pre-1 Po'-t-1 Pr•-2 Pr'e-.3 Pre-4 Pre-5 Audiometer Readings Relative To Therapy   FIG. 4 . Serial changes in hearing threshold levels measured in decibels for 2000, 4000, and 6000 Hz in the ear ipsilateral to the carotid cisplatin infusion. Data points are means ___ standard error of the means in decibels for patients tested prior to each monthly infusion, except for "Post-l," which is 24 hours after the first infusion. Numbers in parentheses indicate patients tested at each point. Audiometer calibrated in accordance with ANSI-1969 specifications (American National Standards Institute).
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never below 3000 ceUs/ml. Five patients had abnormalities of platelets, consisting of a qualitative platelet defect demonstrated by elevations of bleeding time in three.
Only one patient (Case 3) exhibited visual toxicity that could be directly related to the infusion of cisplatin. Toxicity was determined to be a visual field impairment to color targets only, without acuity loss or funduscopic change on the side of the infusion. This visual toxicity was manifested on a delayed basis (after the discontinuation of cisplatin following seven treatments). Interestingly, this patient subsequently underwent reoperation, was treated with alpha-interferon, and is one of the current survivors and the longest-surviving member of the group of initially stable cases.
One patient was considered to have suffered direct cerebral toxicity and dysfunction as a result of the cisplatin infusion. This patient (Case 19) was the only one who underwent infusion of first one and later the other carotid artery following excellent response on the side of the original tumor but progression into the contralateral hemisphere. She had responded to two cisplatin infusions on the ipsilateral side, then showed CT evidence of progression on the contralateral side across the corpus callosum. She developed brain swelling, seen on CT scans within 2 weeks after infusion, on the contralateral side with rapid neurological deterioration, and died 5 weeks following this infusion. No autopsy was permitted.
Discussion
Intra-arterial regional chemotherapeutic infusions offer the prospect of enhancing drug delivery and exposure to neoplastic tissue while possibly minimizing systemic side effects of such agents. The first efforts to apply this approach clinically in brain-tumor patients were reported in the 1950's and the early 1960's and utilized various mustards or amino acid analogs. 4"8"12"27"28 In 1965, Owens, et al., ~s reported the use of vincristine intra-arteriaUy in patients with newly diagnosed or recurrent giiomas. In each of these reports, only a handful of patients were evaluated, and the lack of any encouraging clinical evidence of efficacy was at least partly due to the pharmacology of the agents used and, in some instances, to their central nervous system toxicities.
An understandable void in intra-arterial chemotherapy ensued due to a lack of exciting agents for study until the identification in the 1970's of the effectiveness of systemic BCNU for recurrent malignant gliomas. 3"26 Subsequently, in the 1980's, there have appeared reports of intra-arterial infusions of BCNU in newly diagnosed malignant glioma cases in place of or prior to use of radiotherapy._~.~,.~..6.25 Only a small number of patients were included in each report and there was no randomized study of drug administration. Taking into account the recognized independent predictors of outcome such as age, Karnofsky rating, and histology, it is not possible from these articles to conclude any unique efficacy of regional infusion. Several authors have reported carotid artery infusion of BCNU for recurrent gliomas. 67"925 Responses have been documented both by CT scans and by neurological examination. However, there has been no evidence thus far to prove any superiority of the arterial route of administration, and both ocular and brain toxicities have been reported. Other intraarterial studies with patients who had recurrent gliomas have utilized 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea (PCNU) 2~ and combinations of BCNU, cisplatin, and VM-26 (teniposide). ~~ Unfortunately, most of these studies also include either too few patients or incomplete data on the predictors of outcome to determine efficacy. Also, in those studies where more than one agent was utilized, there is no way to determine whether the two or three agents administered at the same time were any more effective than a single agent.
Intra-arterial chemotherapy performed in conjunction with radiation therapy for newly diagnosed glioma cases was first reported using vinblastine and vincristine in the 1960's. 14,1~ Subsequent studies with nitrosourea compounds have included BCNU and (1-4-amino-2-methyl-5-pyrimidinyl)-methyl-3-(2-chloroethyl)-3-nitrosourea (ACNU). 1,5,17,29 It is difficult to interpret efficacy from these studies because of an absence of information on patient characteristics, too small a number of patients under study, and the need for a randomized study. When a randomized study was undertaken recently by the Brain Tumor Cooperative Group, a significant problem of central neurotoxicity emerged with the concomitant use of intra-arterial BCNU and radiotherapy.13 If intra-arterial chemotherapy is to be used in conjunction with radiotherapy for newly diagnosed cases, it is clear that agents other than BCNU must be identified or schedules of BCNU dosing and infusion techniques must be developed that will minimize the central neurotoxicity effect of BCNU upon normal brain.
Cisplatin and carboplatin have been reasonably unimpressive drugs when administered intravenously to adult patients with glioma. 2 r.24 However, cisplatin with intra-arterial delivery was first studied in 1982 by Stewart, et al., 22 in five patients and in 1984 by Feun, et al., 12 in 22 patients. Feun, et al., reported using cisplatin, 60 to 120 mg/sq m, intra-arterially every 4 weeks, with six responses (judged primarily by CT scan review), four cases of disease stabilization, and nine patients with progression. Encouraged by these studies and realizing the need to identify an agent that might be effective and also useful concomitant with radiation therapy without undue sensitization of normal brain, we initiated the present study in patients with recurrent gliomas. The response rate, judged by objective CT scan tumor volume measurements, was 34%; the mean/ median time to treatment failure for the responding group was 22.6/20.0 weeks and the median survival time was 35.0 weeks for these 12 patients. An additional 40% of the patients with progressing tumors achieved stabilization of their disease for a mean/median of 19.1 / 14.0 weeks; their median survival time was 24.0 weeks. The nine patients (26%) whose disease progressed despite treatment had initial tumor volumes about 16% larger than for the responder and stable groups, but this difference was not statistically significant. The progressive tumor group had a larger proportion of glioblastomas (66%), which may also have played a role in those patients failing to respond.
Several instances of toxicity were noted with the use of intra-arterial cisplatin at 60 mg/sq m/dose. There was no significant renal failure, despite some renal toxicities; one patient had a very mild ocular toxicity, and eight patients had hearing loss (severe in one). One patient who had undergone bilateral carotid infusions for disease progression in the opposite hemisphere suffered central neurotoxicity and died 5 weeks later.
These favorable results in patients with recurrent gliomas treated with intra-arterial cisplatin have now led to the initiation of a study of the use of regional carotid artery cisplatin administered monthly for 4 months prior to beginning radiation therapy in patients with newly diagnosed malignant gliomas. This new study is being offered to patients who have had only tumor biopsy and should permit a precise definition by CT scanning of the relative efficacy of intra-arterial cisplatin occurring prior to initiation of radiation therapy. This investigation should permit further evaluation of the safety of intra-arterial cisplatin administered sequentially prior to and following radiation therapy.
